title: Inhibition of insulin secretion by cerulenin might be due to impaired glucose metabolism.
abstract: BACKGROUND
  Cerulenin, an inhibitor of protein acylation, has been used as a tool to study the potential role of protein acylation in a variety of activities in different cells, and in stimulus-secretion coupling in pancreatic islets and clonal beta-cells.
  
  
  METHODS
  In the present study we investigated its effects on stimulated insulin secretion, glucose metabolism and utilization, oxygen consumption and ATP levels.
  
  
  RESULTS
  In isolated rat pancreatic islets, cerulenin pre-treatment (100 microM) inhibited insulin secretion in response to glucose, and to the non-hydrolysable analogue of leucine, aminobicyclo-[2,2,1]heptane-2-carboxylic acid (BCH). These data are in accord with the hypothesis that protein acylation could be involved in the stimulation of insulin secretion. However, we also found that cerulenin profoundly decreased glucose oxidation, glucose utilization, oxygen consumption and ATP levels. Consequently, decreased metabolism provides an alternative mechanism to inhibition of protein acylation that could explain the inhibition of insulin secretion by cerulenin.
  
  
  CONCLUSIONS
  Inhibition of insulin secretion by cerulenin can no longer be taken as evidence in favour of a role for protein acylation in the control of insulin release. As protein acylation is known to be involved in the normal functioning of proteins in stimulus-secretion coupling and exocytosis, more direct approaches to understand its role(s) are required.
authors.affiliation: The Department of Molecular Medicine, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA. sgs4@cornell.edu
authors.forename: Susanne G
authors.initials: SG
authors.lastname: Straub
authors.forename: Geoffrey W G
authors.initials: GW
authors.lastname: Sharp
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002569:Cerulenin / Q000494:pharmacology*; D005947:Glucose / Q000378:metabolism; D018149:Glucose Intolerance / Q000503:physiopathology*; D006019:Glycolysis; D007328:Insulin / Q000378:metabolism*; D007329:Insulin Antagonists / Q000494:pharmacology*; D000078790:Insulin Secretion; D008297:Male; D010084:Oxidation-Reduction; D010101:Oxygen Consumption; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D007328:Insulin; D007329:Insulin Antagonists; D002569:Cerulenin; D000255:Adenosine Triphosphate; D005947:Glucose